Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Glucotrack Inc. (GCTK:NASDAQ), powered by AI.
Glucotrack Inc. is currently trading at $0.73. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Glucotrack Inc. on Alpha Lenz.
Glucotrack Inc.'s P/E ratio is -0.0.
“Glucotrack Inc. trades at a P/E of -0.0 (undervalued) with strong ROE of 461.0%.”
Ask for details →Glucotrack Inc. is a company dedicated to developing non-invasive glucose monitoring technology. The core purpose of the company is to provide an alternative method for individuals with diabetes to track their blood glucose levels without the need for frequent finger-prick tests. This innovation primarily serves the healthcare and biotechnology sectors, offering a user-friendly solution that aims to improve patient comfort and compliance. The Glucotrack device is designed to measure glucose levels using several physiological parameters detected via an ear clip, conveying real-time data that can be crucial for metabolic management. Its focus on non-invasive technology positions it as a potential game-changer in the realm of diabetic care, especially considering the global prevalence of diabetes. In the broader market context, Glucotrack Inc. represents a significant development within the medtech industry, with its efforts reflecting an ongoing trend towards more patient-centered, convenient healthcare solutions. Its contribution lies not only in its innovative approach but also in its potential to reduce the physical and psychological barriers associated with traditional glucose monitoring methods.
“Glucotrack Inc. trades at a P/E of -0.0 (undervalued) with strong ROE of 461.0%.”
Ask for details →Glucotrack Inc. (ticker: GCTK) is a company listed on NASDAQ in the Healthcare sector (Medical Instruments & Supplies). It has approximately 11 employees. Market cap is $4,043.
The current price is $0.735 with a P/E ratio of -0x and P/B of -0x.
ROE is 461.02%.